Which company develops, produces and drug background of Tazemetostat?

Tazemetostat (Tazemetostat, trade name Tazverik) is a first-in-class oral EZH2 inhibitor developed by the American biopharmaceutical company Epizyme, Inc. R&D and production. Epizyme is an innovative company focused on the research and development of epigenetic drugs. The launch of tazerestat marks an important breakthrough for the company in the field of epigenetic targeted therapy. Later, Epizyme was acquired by the French pharmaceutical company Ipsen in 2022 , so the global promotion and commercialization of the drug is currently Ipsen is responsible.

Tazerestat is a small molecule drug that selectively inhibits EZH2 (enhancer homolog 2). EZH2 is a key methyltransferase of the polycomb repressive complex (PRC2), involved in chromatin remodeling and gene silencing. In some malignant tumors, the EZH2 gene is mutated or overactivated, leading to abnormal proliferation of tumor cells. By inhibiting EZH2, tazerestat can restore the expression of tumor suppressor genes and block the growth of tumor cells. This is one of the first approved epigenetic targeted inhibitors and is groundbreaking.

In 2020, the United StatesFDA approved tazerestat for the treatment of relapsed or refractory metastatic epithelioid sarcoma (epithelioid sarcoma) Adult and adolescent patients over 16 years old, this is the first approved indication for this drug. Subsequently, it was also approved for use in follicular lymphoma (follicular lymphoma), especially EZH2 mutation-positive or relapsed / refractory patients. Clinical trials have shown that tazerestat can achieve long-term disease control in some patients, providing a new treatment option for this type of rare malignant tumors.

As an innovative epigenetic drug, tazerestat fills the gap in the treatment of some rare tumors. Its research and development background reflects the potential of epigenetic regulation in precision cancer medicine. Although the current indications are relatively limited, ongoing clinical trials cover other malignant tumors, including diffuse large BB cell lymphoma, ovarian cancer, etc. If the scope of indications can be expanded in the future, tazetostat is expected to become one of the representative drugs for epigenetic drug treatment of tumors.

Reference materials:https://www.drugs.com/